Sinocare iCan i6
Sinocare
What it is
A smaller iCan CGM family commercialized in China, with 15-day wear and three-minute updates. The international page explicitly excludes sales in the UK and many EU countries; those markets are not marked available.
Editorial review: .
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Accuracy: Manufacturer MARD claim; independent model-specific accuracy not verified.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 45 × 20 + 45 × 15 + 12 × 15 + 88 × 10 + 80 × 10 + 60 × 10 + 90 × 10 + 0 × 5 + 35 × 5 = 5110; divide by total weight 100. Unrounded weighted result: 51.1.
Editor’s take
Scores are editorial judgments about the evidence and practical features, not measured comparative performance or a probability of success.
The full picture
Sinocare’s Chinese product history dates the i6 family’s commercialization to 2025. The international i6 page specifies 15-day wear, three-minute readings and approximately 2 g hardware. It lists age 2+, with age-dependent insertion sites.21
The page explicitly says products shown are not sold in the UK and a long list of EU countries. A UK-subdomain product page therefore does not establish UK availability. Current local registration and reimbursement outside China remain unverified.1
The advertised adult MARD is a manufacturer claim. The i3 pediatric paper is not assumed to validate every i6 hardware variant. No commercial AID compatibility is established by the sources checked.
Sources
- [1]
- [2]